
**UPDATES ON PROCEEDINGS COMMENCED BY
WEIXIN HOSPITAL INVESTMENT MANAGEMENT (SHANGHAI) CO. LTD**

- 1.1 The Board of Directors of OUE Lippo Healthcare Limited (the “**Company**”) refers to the Company’s announcements from 22 February 2017 to 29 November 2019 in relation to the on-going litigation with Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理 (上海) 有限公司) (“**Weixin**”).¹
- 1.2 As announced previously on 23 August 2018, Weixin commenced legal proceedings against Wuxi Yilin Real Estate Development Co Ltd (无锡医霖置业发展有限公司) (“**Wuxi Yilin Real Estate**”) and Wuxi New District Phoenix Hospital Co., Ltd (无锡新区凤凰医院有限责任公司) (“**Wuxi Co.**”) to seek a declaration that the land transfer agreement between Wuxi Yilin Real Estate and Wuxi Co. dated 15 January 2015 is void.
- 1.3 As announced on 25 November 2019, the Wuxi Xinwu District Court issued its judgment on 22 November 2019 wherein it dismissed Weixin’s application and held that the land transfer agreement between Wuxi Yilin Real Estate and Wuxi Co is legitimate and binding on all relevant parties. The Court also ordered Weixin to pay the Court’s fees for the proceedings (the “**Wuxi Judgment**”).
- 1.4 On 12 December 2019, the Company was informed by its People’s Republic of China counsel that Weixin has appealed against the Wuxi Judgment on 4 December 2019 to the Wuxi Intermediate District Court. A hearing has not been fixed for this appeal.
- 1.5 The Company has been advised by its People’s Republic of China counsel that there is no merit in the appeal, and Wuxi Yilin Real Estate has instructed their People’s Republic of China counsel to vigorously defend the appeal.
- 1.5 The Company will provide further updates on the status of the above matters through SGXNET in accordance with the requirements under the applicable Catalist Rules.

¹ Please refer to the Company’s announcements dated 22 February 2017, 20 December 2017, 6 August 2018, 23 August 2018, 30 November 2018, 5 December 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019, 31 May 2019, 28 June 2019, 30 July 2019, 30 August 2019, 30 September 2019, 14 October 2019, 30 October 2019, 25 November 2019 and 29 November 2019.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
12 December 2019

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

OUE Lippo Healthcare Limited
Company Registration No. 201304341E
(In receivership over charged shares in certain subsidiaries)
6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809
T: +65 6578 9188 F: 64794647 www.ouelh.com